78.6 F
Boston
HomeMedicineRevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board

RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board

Internationally renowned ophthalmologist and investment leader joins to support advancement of disruptive ophthalmic treatments

SAN CARLOS, Calif., May 3, 2024 /PRNewswire/ — RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today the appointment of Dr. Emmett Cunningham to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham, a distinguished figure in the ophthalmic and investment communities, brings more than twenty years of experience as a full-time entrepreneur and investor to his new role with RevOpsis.